Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arcus Biosciences closes $107mm Series C round

Executive Summary

Arcus Biosciences Inc. (cancer immunotherapies) raised $107mm through its Series C round. GV (formerly Google Ventures) led and was joined by new investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital, and entities affiliated with Leerink Partners. Returning backers The Column Group, Foresite Capital, Invus Opportunities, DROIA, Celgene, and Taiho Ventures also participated. The round will support continued development of Phase I projects AB928 (dual adenosine receptor antagonist) and AB122 (PD-1 antibody), as well as preclinical candidates AB680 (CD73 inhibitor) and AB154 (TIGIT antibody).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies